Tumor drug shows promise for Tasmanian devils, pets and maybe humans

07/1/2013 | Sydney Morning Herald (Australia), The

A new plant-derived drug, EBC-46, was associated with regression or palliation in cancerous tumors in four Tasmanian devils, which have suffered massive losses to a contagious cancer. Veterinarian Jack Ayerbe, a director with the company that developed the drug, says he's used it successfully to treat some dogs and cats in his practice. Veterinarian Stephen Pyecroft, who helped develop and test the drug, says it may help treat captive devils and improve survival of their young, but it won't be a feasible treatment for wild animals. Human trials are planned as well.

View Full Article in:

Sydney Morning Herald (Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL